Beta Drugs peers

·UnclassifiedChart ›

Companies like Beta Drugslatest year

Beta DrugsBETA · FY26 · this company
Market cap₹1,875
P/E45.20×
Sales growth−32.5%
ROE18.8%
Thejo EngineeringTHEJO · FY26
Open ›
Market cap₹2,055
P/E41.72×
Sales growth+31.0%
ROE15.1%
Macpower CNC MachinesMACPOWER · FY26
Open ›
Market cap₹1,950
P/E57.57×
Sales growth+40.4%
ROE21.3%

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BETA₹1,849.70

Beta Drugs Limited

· Unclassified
₹ CrorePeersTHEJOMACPOWERSAKARSERVOTECHMcap ₹1,875 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
BETA
FY26
GAJA
no data
THEJO
FY26
MACPOWER
FY26
Peer
Average
Valuation — at last close
P/E45.20×—◆ 41.72×57.57×49.65× -9%
P/B7.66×—◆ 5.80×11.13×8.46× -9%
EV/EBITDA◆ 25.08×—25.20×36.01×30.61× -18%
Market Cap₹1,875 Cr—₹2,055 Cr₹1,950 Cr₹2,003 Cr -6%
Growth
Revenue CAGR 3Y———18.17%18.17%
Revenue CAGR 5Y———24.17%24.17%
Net Income CAGR 3Y———37.99%37.99%
Revenue YoY (latest Q)-32.47%—31.02%◆ 40.38%35.70% -191%
Net Income YoY (latest Q)-19.37%—◆ 56.10%43.71%49.91% -139%
Profitability
EBITDA Margin◆ 19.67%—12.67%16.20%14.43% +36%
Net Income Margin◆ 10.78%—7.73%10.17%8.95% +20%
Return on Common Equity18.78%—15.11%◆ 21.30%18.20% +3%
Return on Capital Employed16.23%—17.05%◆ 28.52%22.79% -29%
Return on Assets8.90%—9.82%◆ 14.01%11.91% -25%
Credit & Quality
Total Debt/Equity0.60×—0.01×◆ 0.00×0.01× +11900%
Interest Coverage3.82×—12.37×◆ 29.74×21.05× -82%
Scale — latest FY
Revenue / Total Income₹385 Cr—₹632 Cr₹333 Cr₹483 Cr -20%
Net Income₹41.5 Cr—₹48.8 Cr₹33.9 Cr₹41.4 Cr 0%
Total Assets₹496 Cr—₹549 Cr₹265 Cr₹407 Cr +22%
EPS₹40.92—₹45.41₹33.86₹39.64 +3%
Book Value per Share₹241.47—₹326.73₹175.17₹250.95 -4%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.